Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: Therapeutic consequences? [1]

European Journal of Clinical Pharmacology

Volumn 55, Issue 11-12, 2000, Pages 877-879

  Haffen, E ^a   Vandel, P ^a   Paintaud, G ^a   Broly, F ^a   Vandel, S ^a   Bonin, B ^a   Bizouard, P ^a   Sechter, D ^a   Bechtel, P R ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CYAMEMAZINE; DEBRISOQUINE 4 HYDROXYLASE; LEVOMEPROMAZINE; PERICIAZINE; THIORIDAZINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT;

ADULT; AGED; ALLELISM; DEPRESSION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; ADOLESCENT; ALLELE; GENETICS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; FEMALE; GENOTYPE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHENOTYPE; TREATMENT OUTCOME;

EID: 0033625290     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050711     Document Type: Letter

References (16)